Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6331 AL 6345

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study

Kavanagh S, Van Baelen B, Schäuble B.

J Alzheimers Dis. 2011;27(3):521-30. doi: 10.3233/JAD-2011-110417.

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 Investigators.

Neurology. 2011 Sep 27;77(13):1253-62. doi: 10.1212/WNL.0b013e3182309fa5. Epub 2011 Sep 14.

Alzheimer's therapeutics: translation of preclinical science to clinical drug development

Savonenko AV, Melnikova T, Hiatt A, Li T, Worley PF, Troncoso JC, Wong PC, Price DL.

Neuropsychopharmacology. 2012 Jan;37(1):261-77. doi: 10.1038/npp.2011.211. Epub 2011 Sep 21.

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease

Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS.

J Clin Psychiatry. 2012 Jan;73(1):121-8. doi: 10.4088/JCP.10m06574. Epub 2011 Sep 6.

MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, Rosen A, O'Hara R, Fairchild JK, Spielman D, Yesavage JA.

J Alzheimers Dis. 2011;26 Suppl 3(0 3):331-6. doi: 10.3233/JAD-2011-0021.

Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation

Trebbastoni A, Gilio F, D'Antonio F, Cambieri C, Ceccanti M, de Lena C, Inghilleri M.

Clin Neurophysiol. 2012 May;123(5):902-9. doi: 10.1016/j.clinph.2011.09.010. Epub 2011 Oct 12.

Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge

Siciliano R, Barone E, Calabrese V, Rispoli V, Butterfield DA, Mancuso C.

CNS Neurol Disord Drug Targets. 2011 Nov;10(7):766-76. doi: 10.2174/187152711798072356.

[Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia]

Gavrilova SI, Kalyn IaB, Kolykhalov IV, Roshchina IF, Selezneva ND.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(9):16-22.

Charting the path for early diagnosis and prevention of Alzheimer's disease

Quiroz YT, Lopera F, Budson AE.

Expert Rev Neurother. 2011 Dec;11(12):1665-7. doi: 10.1586/ern.11.162.

[Therapy of psycho-behavioral disorders in the elderly]

Gallarda T.

Encephale. 2011 Sep;37(4 Suppl 4):H26-8. doi: 10.1016/S0013-7006(11)70031-8.

Memantine in everyday clinical practice: a comparison of studies in Germany and Greece

Förstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M.

Dement Geriatr Cogn Disord. 2011;32(4):267-72. doi: 10.1159/000334991. Epub 2012 Jan 9.

[New conception of Alzheimer's disease and the strategy for preclinical therapy]

Miyagawa T, Iwata A.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:252-6.

Staged decline of visual processing capacity in mild cognitive impairment and Alzheimer's disease

Bublak P, Redel P, Sorg C, Kurz A, Förstl H, Müller HJ, Schneider WX, Finke K.

Neurobiol Aging. 2011 Jul;32(7):1219-30. doi: 10.1016/j.neurobiolaging.2009.07.012. Epub 2009 Aug 26.

Potential predictors of hippocampal atrophy in Alzheimer's disease

Dhikav V, Anand K.

Drugs Aging. 2011 Jan 1;28(1):1-11. doi: 10.2165/11586390-000000000-00000.

Scientific truth or false hope? Understanding Alzheimer's disease from an aging perspective

Chen M, Maleski JJ, Sawmiller DR.

J Alzheimers Dis. 2011;24(1):3-10. doi: 10.3233/JAD-2010-101638.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias